Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab

Patient Enrollment Complete For Phase III Stelara Biosimilar Study

Executive Summary

Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.

You may also be interested in...



Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition

Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track. 

Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

Coherus Moves Ahead With Pegfilgrastim On-Body Injector Rival

Coherus BioSciences is eyeing a potential late 2022/early 2023 timeline to introduce its proposed proprietary on-body injector device for its Udenyca pegfilgrastim biosimilar, after reporting positive results from a comparative clinical trial.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel